Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

8211; Data from the first randomized, placebo-controlled study evaluating the reduction of liver iron concentration and serum ferritin in patients with non-transfusion-dependent thalassemia after one year of treatment with Exjade oral iron chelation therapy (ASH abstract #902; December 13, 7:30 – 9:00AM) and data from a retrospective analysis of hematological response during iron chelation therapy in patients with myelodysplastic syndrome (MDS) and aplastic anemia with transfusional iron overload (ASH abstract #611; December 12, 2:45 – 4:15PM).
  • INC424 – Data from multiple research programs will be presented, including two pivotal Phase III studies evaluating INC424 benefit versus placebo (COMFORT-I [COntrolled MyeloFibrosis study with ORal JAK inhibitor Therapy]) (ASH abstract #278; December 12, 7:00 – 8:30AM) and versus best available therapy (COMFORT-II) (ASH abstract #795; December 12, 4:30 – 6:00PM). These data will assess measures of spleen reduction, symptom improvement, health-related quality of life and overall survival.
  • Everolimus – Results from a Phase II study evaluating everolimus as a monotherapy in relapsed/refractory Hodgkin lymphoma (ASH abstract #2717; December 11, 6:00 – 8:00PM) and data from a Phase I trial of everolimus in combination with rituximab or in combination with BTZ and rituximab in relapsed/refractory Waldenstrom's macroglobulinemia (ASH abstract #2705; December 11, 6:00 – 8:00PM).
  • LBH589 – Results from PANORAMA-2 (PANobinostat ORAl in Multiple myelomA), a Phase II study of LBH589 in combination with BTZ and dexamethasone in patients with relapsed and BTZ-refractory multiple myeloma (ASH abstract #814; December 12, 4:30 – 6:00PM). Data from two trials in myelofibrosis: final results from a Phase I trial of prolonged low dose therapy with LBH589 in myelofibrosis patients (ASH abstract #794; December 12, 4:30 – 6:00PM) and a precl
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related biology technology :

    1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
    2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
    3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
    4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
    5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
    6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
    7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
    8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
    9. Novartis Class Awarded $250 Million in Punitive Damages
    10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
    11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/27/2015)... 27, 2015 Elsevier , a ... services, and Qatar University Research Office   have announced the ... The awards ceremony, held last week at ... attended by more than 40 guests representing Qatar,s ... by Professor Sheikha Abdulla Al-Misnad , President of ...
    (Date:4/24/2015)... (PRWEB) April 24, 2015 Leading ... milestones in its allogeneic stem-cell product development program ... properly reflect the corporate strategic direction. , “I ... (donor) adipose stem cell development program has been ... our cGMP manufacturing facility and hiring of our ...
    (Date:4/24/2015)... , April 24, 2015 /CNW Telbec/ - Mirego, leader in ... the making of three mobile app extensions for the all ... for its clients, Familiprix, OMSignal and MediaMiser, these extensions will ... to functions designed specifically for wrist use.  ... Watch is a highly customizable tactile smartwatch that makes for ...
    (Date:4/23/2015)... 24, 2015 Ralco announced today that ... Nutrition® (ABN) for the exclusive worldwide rights to sell ... technology is a new in-line milk system that increases ... them to move supplementation milk cups within a farrowing ... “This technology lets producers get Birthright™ milk to the ...
    Breaking Biology Technology:Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 2Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 3Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 4Elsevier Announces the Winners of Qatar University Scientists 2015 Scopus Awards 5Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Ralco Acquires License to Birthright™ Moveable Milk Cup 2
    ... Both recombinant human , ... vitro to cleave long dsRNA, producing siRNA cocktails that are , ... (1-6). Dicer is an , ... enzyme responsible for cleavage of long dsRNAs to siRNA in the , ...
    ... Gene Specific siRNA Controls , ... research or you are an siRNA expert, ... the Silencer gene specific siRNA , ... contains 50 g of ready-to-use chemically synthesized and gel , ...
    ... siRNA designs now available , ... , ... highly effective siRNAs , High quality custom siRNA synthesis from The RNA Company ... choice of synthesis options , Premium ...
    Cached Biology Technology:Dicer vs. RNase III for Preparation of siRNA Cocktails 2Dicer vs. RNase III for Preparation of siRNA Cocktails 3Control Your siRNA Research 2Control Your siRNA Research 3Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 2Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 3Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 4Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 5Cenix-Designed siRNAs for 95% of Human and Mouse Genomes 6
    (Date:4/2/2015)... , April 2, 2015 Fingerprint ... fingerprint sensor FPC1025 from the distributor World Peace Industrial ... during Q2 2015 although the major part of the ... will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + ...
    (Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
    (Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
    Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
    ... Clough has developed a novel method for eavesdropping ... bursts. The doctoral student at Rensselaer Polytechnic Institute ... waves to boost the distance from which researchers ... hidden explosives, chemicals, and other dangerous materials. ...
    ... Ever get a flu shot and still get the flu? If ... come thanks to a new discovery by researchers who found that ... ability of flu vaccines to ward off this deadly virus. A ... Journal of Leukocyte Biology ( http://www.jleukbio.org ) suggests that ...
    ... why primates differ from other mammals, and humans differ from ... genome that were once considered "junk." A new study ... Medicine finds that when a particular type of repetitive DNA ... genes, they can alter the rate at which proteins are ...
    Cached Biology News:Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 2Student innovation at Rensselaer holds key to safer remote detection of dangerous materials 3Drug to fight tumors also fights the flu and possibly other viruses 2U. Iowa team investigates function of 'junk DNA' in human genes 2U. Iowa team investigates function of 'junk DNA' in human genes 3
    ... Buffers are membrane-filtered isotonic and enzyme-free ... and cell-conditioning agents in either Ca2+- ... or Ca2+- and Mg2+-free phosphate-buffered ... cells from support substrates and each ...
    ...
    ... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
    Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
    Biology Products: